Protein Engineered Cas-CLOVER Yields 99% Gene Editing Efficiency and Ultra-Low Toxicity

At the 2022 Bioprocessing Summit, Demeetra’s Corey Brizzee presented Cas-CLOVER’s mechanism and newly engineered variants. This proven platform is enabling gene editing with extremely high efficiency and very low cell toxicity.

View the presentation below.

Learn more about Cas-CLOVER

Read our Peer-reviewed Publications

Schedule a call with us to learn more.